<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[novo nordisk Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/novo+nordisk.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to novo nordisk]]></description>
	<s:counts start="0" returned="3" found="3" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Novo Nordisk Executive Compensation: A Picture of Modesty (Except for the Car Expenses)]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001020/novo-nordisk-executive-compensation-a-picture-of-modesty-except-for-the-car-expenses/]]></link>
		<description><![CDATA[Novo Nordisk's annual report is out and it contains some interesting stuff on senior management compensation. CEO Lars Rebien SÃ¸rensen received total compensation of DKK10.8 million (about $1.8 million).    That was modest compared to his counterparts at American companies. (At Eli Lilly, CEO John Lechleiter got $13...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 17 Feb 2009 09:38:37 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/car.html"><![CDATA[Car]]></category>
		<category domain="http://resources.bnet.com/topic/compensation.html"><![CDATA[Compensation]]></category>
		<category domain="http://resources.bnet.com/topic/novo+nordisk.html"><![CDATA[Novo Nordisk]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Novo Nordisk's Liraglutide Logos Leak Out Before Approval]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000486/novo-nordisks-liraglutide-logos-leak-out-before-approval/]]></link>
		<description><![CDATA[    UPDATE: As BNET predicted, the new Novo Nordisk logos have been suddenly removed from the web. You can still see a Google cache of the page here, and a screen grab here.     Novo Nordisk's new diabetes drug, liraglutide, isn't approved by the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 11 Dec 2008 08:24:31 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/logo.html"><![CDATA[Logo]]></category>
		<category domain="http://resources.bnet.com/topic/novo+nordisk.html"><![CDATA[Novo Nordisk]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Novo Nordisk Expands R&D Presence in China with New Manufacturing Plant]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F105326-novo-nordisk-expands-r-d-presence-in-china-with-new-manufacturing-plant%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Novo Nordisk NVO will invest almost $400 million to build a very large insulin manufacturing facility in Tianjin. The new facility will function as the company&#8217;s primary production site in China and serve the entire Asia Pacific region. The new 22,500 sq. meter plant, which will...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 11 Nov 2008 05:16:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/facility.html"><![CDATA[Facility]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/r%2526d.html"><![CDATA[R&D]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/novo+nordisk.html"><![CDATA[Novo Nordisk]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/nuvo+network+management+inc..html"><![CDATA[NUVO Network Management Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVO</category>
		<category domain="tickers">NVO</category>
	</item>
</channel>
</rss>
